CCS1477, a first-in-class small molecule to treat prostate (CRPC) and other cancersP300/CBP bromodomain inhibitor CCS1477
CCS1477 inhibits the bromodomains of twin histone acetyl transferase proteins, p300/CBP
Other cancer tumours are also susceptible to p300/CBP inhibition, notably specific haematological, bladder and lung cancers.
Backed by strong pre-clinical data, CCS1477 is now heading to clinical trials.
CellCentric’s scientific foundation is in epigenetics. Having originally spun out of the University of Cambridge, the company has investigated over 50 epigenetic-related targets before focusing on p300/CBP.
Therapeutic targeting of the p300/CBP bromodomain for the treatment of castration resistant prostate cancer (CRPC)
Targeting the bromodomain of p300/CBP for the treatment of castrate resistant prostate cancer
Characterisation of CCS1477: A novel mall molecule inhibitor of p300/CBP for the treatment of CRPC
Novel small molecule inhibitors of p300/CBP down-regulate AR and c-Myc for the treatment of CRPC
A novel small molecule inhibitor of p300/CBP for the treatment of CRPC – preclinical evaluation
CellCentric’s team has deep experience of drug discovery and development in oncology
CellCentric’s first-in-class p300/CBP inhibitor drug CCS1477; capsule production complete ready for the clinic
March 7th 2018
Production of CCS1477 in capsule form is now complete, ahead of forthcoming first-in-human clinical trials to investigate the novel drug’s tolerability and efficacy in treating late stage prostate cancer (CRPC). The active component is a p300/CBP bromodomain inhibitor that has a profound effect on the drivers of CPRC. It addresses the resistance seen in tumours treated with current second generation anti-hormonal drugs. Formulation and GMP manufacture of the capsules was carried out by Quay Pharma.
CCS1477; new collaborations announced exploring p300/CBP inhibition for prostate cancer treatment
January 31st 2018
CellCentric and The Institute of Cancer Research, London, have signed a research agreement to further explore the effects of CellCentric’s drug candidate CCS1477 on prostate cancer. In addition, Karen Knudsen, Johann de Bono and Myles Brown have been granted a Prostate Cancer Foundation challenge award of $1m to investigate the molecular and biological effects of CCS1477 in the context of clinical impact.
CellCentric’s p300/CBP bromodomain inhibitor is clearly differentiated from BET inhibitors
December 4th 2017
CellCentric today presents its latest pre-clinical efficacy data on drug Candidate CCS1477, at the AACR’s Annual Prostate Cancer meeting, Orlando. This novel inhibitor which targets the bromodomain of p300/CBP, is advancing to the clinic early 2018. Latest results continue to support CCS1477’s anti-cancer efficacy, as well as its clear differentiation versus other epigenetic-related inhibitors targeting bromodomains (BET inhibitors), such as JQ-1, iBET-151 and OTX-015.
Will, Neil & Nigel will be at AACR18. Further data to be shared on CCS1477 for prostate (CRPC) and other cancers. pic.twitter.com/BIafm3impz